Abstract
Clinical observations and experimental work suggested that inflammatory cells attracted to the brain exert a nonspecific antineoplastic effect. Intralesional treatment of implanted malignant murine brain tumors (KHT sarcomas) with killed Corynebacterium parvum produced an inflammatory cell infiltrate and increased survival in C3H mice relative to that in untreated control C3H mice. This antitumor effect was enhanced when recombinant interleukin-2 was sequentially added as a second intralesional immunomodifier. A high percentage of mice so treated were cured. Inflammatory cells in the brains of treated mice divided for 1-2 weeks, and metabolic activity of astrocytes increased. These findings form the basis for a recently initiated immunotherapy protocol in patients with recurrent glioblastoma multiforme.
Publication types
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
MeSH terms
-
Animals
-
Bacterial Vaccines / administration & dosage
-
Bacterial Vaccines / immunology
-
Bacterial Vaccines / therapeutic use*
-
Brain Neoplasms / therapy*
-
Corynebacterium / immunology*
-
Female
-
Immunotherapy*
-
Inflammation / immunology
-
Injections, Intralesional
-
Interleukin-2 / administration & dosage
-
Interleukin-2 / immunology
-
Interleukin-2 / therapeutic use*
-
Mice
-
Mice, Inbred C3H
-
Neoplasm Transplantation
-
Recombinant Proteins / administration & dosage
-
Recombinant Proteins / immunology
-
Recombinant Proteins / therapeutic use
-
Sarcoma, Experimental / therapy*
-
Vaccines, Inactivated / administration & dosage
-
Vaccines, Inactivated / immunology
-
Vaccines, Inactivated / therapeutic use
Substances
-
Bacterial Vaccines
-
Interleukin-2
-
Recombinant Proteins
-
Vaccines, Inactivated